Story perspectives

Lilly Raises 2026 Revenue Outlook After 48% Q2 Surge

By Drooid · Oct 19, 2026, 8:02 AM UTC · How we work

Summary

Story summary

Eli Lilly reported Q2 2026 revenue of $22.97 billion, a 48% year-over-year increase.
The company raised its 2026 revenue outlook to $85-87 billion and margin target to 49%-50.5%.
Sales volume rose 60% while average selling price fell 13%, partially offset by a stronger product mix.
Lilly pledged $4.5 billion for Indiana manufacturing expansion and a $750 million joint investment with Resilience in Cincinnati.

History

Historical Context

Pfizer’s sildenafil, synthesized in 1989, received FDA approval on 27 March 1998 and quickly became a blockbuster, with U.S. sales peaking at $1.934 billion in 2008 and capturing 92 % of the global erectile-dysfunction market by 2000. That success spurred industry-wide investment, a trend echoed today as Eli Lilly reports $22.97 billion Q2 2026 revenue and pledges a $4.5 billion Indiana plant expansion.

1 of 2

Story summary

Eli Lilly reported Q2 2026 revenue of $22.97 billion, a 48% year-over-year increase.
The company raised its 2026 revenue outlook to $85-87 billion and margin target to 49%-50.5%.
Sales volume rose 60% while average selling price fell 13%, partially offset by a stronger product mix.
Lilly pledged $4.5 billion for Indiana manufacturing expansion and a $750 million joint investment with Resilience in Cincinnati.

1 / 2